CNTX
Context Therapeutics Inc.
Biotechnology
Market Cap$214M
5Y Perf.-59.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CNTX vs AGEN
Revenue, margins, valuation, and 5-year total return — side by side.
AGEN
Agenus Inc.
Biotechnology
Market Cap$132M
5Y Perf.-95.1%
CNTX vs AGEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CNTX | AGEN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $214M | $132M |
| Revenue (TTM) | $0.00 | $114M |
| Net Income (TTM) | $-40M | $115K |
| Gross Margin | — | 35.7% |
| Operating Margin | — | -17.7% |
| Forward P/E | — | 1.8x |
| Total Debt | $112K | $10M |
| Cash & Equiv. | $66M | $3M |
CNTX vs AGEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CNTX
AGEN
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Context Therapeutic… (CNTX) | 100 | 40.5 | -59.5% |
| Agenus Inc. (AGEN) | 100 | 4.9 | -95.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNTX vs AGEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CNTX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Agenus Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
CNTX
Context Therapeutics Inc.
The Income Pick
CNTX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.46
- -54.3% 10Y total return vs AGEN's -94.3%
- Lower volatility, beta 0.46, Low D/E 0.2%, current ratio 8.52x
Best for: income & stability and long-term compounding
AGEN
Agenus Inc.
The Growth Play
AGEN is the clearest fit if your priority is growth exposure.
- Rev growth 10.4%, EPS growth 100.0%, 3Y rev CAGR 5.2%
- 10.4% revenue growth vs CNTX's -45.5%
- 0.1% ROA vs CNTX's -54.8%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AGEN | 10.4% revenue growth vs CNTX's -45.5% |
| Quality / Margins | CNTX | 4.9% margin vs AGEN's 0.1% |
| Stability / Safety | CNTX | Beta 0.46 vs AGEN's 2.72 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CNTX | +201.4% vs AGEN's +27.1% |
| Efficiency (ROA) | AGEN | 0.1% ROA vs CNTX's -54.8% |
CNTX vs AGEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
CNTX vs AGEN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCNTXLAGGINGAGEN
AGENAgenus Inc.
2leads
CNTXContext Therapeutics …
2leads
6 Total Categories
CATEGORYLEADERvs AGENMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AGEN1/1
Valuation MetricsMultiples, price ratios, and targets
AGEN1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
CNTX6/6
Risk & VolatilityBeta, volatility, and downside exposure
CNTX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AGEN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AGEN and CNTX operate at a comparable scale, with $114M and $0 in trailing revenue.
| Metric | CNTXContext Therapeut… | AGENAgenus Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $114M |
| EBITDAEarnings before interest/tax | -$43M | -$10M |
| Net IncomeAfter-tax profit | -$40M | $115,000 |
| Free Cash FlowCash after capex | -$21M | -$159M |
| Gross MarginGross profit ÷ Revenue | — | +35.7% |
| Operating MarginEBIT ÷ Revenue | — | -17.7% |
| Net MarginNet income ÷ Revenue | — | +0.1% |
| FCF MarginFCF ÷ Revenue | — | -139.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +27.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -80.0% | +85.3% |
AGEN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
AGEN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | CNTXContext Therapeut… | AGENAgenus Inc. |
|---|---|---|
| Market CapShares × price | $214M | $132M |
| Enterprise ValueMkt cap + debt − cash | $148M | $140M |
| Trailing P/EPrice ÷ TTM EPS | -6.13x | -1102.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 1.79x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.16x |
| Price / BookPrice ÷ Book value/share | 3.67x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
AGEN leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — CNTX and AGEN each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs CNTX's 3/9, reflecting solid financial health.
| Metric | CNTXContext Therapeut… | AGENAgenus Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -60.0% | — |
| ROA (TTM)Return on assets | -54.8% | +0.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -50.9% | — |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$66M | $7M |
| Cash & Equiv.Liquid assets | $66M | $3M |
| Total DebtShort + long-term debt | $112,064 | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | 1.11x |
Evenly matched — CNTX and AGEN each lead in 2 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
CNTX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CNTX five years ago would be worth $4,569 today (with dividends reinvested), compared to $611 for AGEN. Over the past 12 months, CNTX leads with a +201.4% total return vs AGEN's +27.1%. The 3-year compound annual growth rate (CAGR) favors CNTX at 56.7% vs AGEN's -51.0% — a key indicator of consistent wealth creation.
| Metric | CNTXContext Therapeut… | AGENAgenus Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +50.3% | +16.1% |
| 1-Year ReturnPast 12 months | +201.4% | +27.1% |
| 3-Year ReturnCumulative with dividends | +285.1% | -88.2% |
| 5-Year ReturnCumulative with dividends | -54.3% | -93.9% |
| 10-Year ReturnCumulative with dividends | -54.3% | -94.3% |
| CAGR (3Y)Annualised 3-year return | +56.7% | -51.0% |
CNTX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
CNTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CNTX is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CNTX currently trades 64.4% from its 52-week high vs AGEN's 51.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CNTXContext Therapeut… | AGENAgenus Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 2.72x |
| 52-Week HighHighest price in past year | $3.62 | $7.34 |
| 52-Week LowLowest price in past year | $0.49 | $2.71 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +51.1% |
| RSI (14)Momentum oscillator 0–100 | 48.4 | 48.8 |
| Avg Volume (50D)Average daily shares traded | 901K | 814K |
CNTX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CNTX as "Buy" and AGEN as "Buy". Consensus price targets imply 125.3% upside for CNTX (target: $5) vs 95.5% for AGEN (target: $7).
| Metric | CNTXContext Therapeut… | AGENAgenus Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $5.25 | $7.33 |
| # AnalystsCovering analysts | 6 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
AGEN leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). CNTX leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallContext Therapeutics Inc. (CNTX)Leads 2 of 6 categories
Loading custom metrics...
CNTX vs AGEN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CNTX or AGEN a better buy right now?
Analysts rate Context Therapeutics Inc.
(CNTX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CNTX or AGEN?
Over the past 5 years, Context Therapeutics Inc.
(CNTX) delivered a total return of -54. 3%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: CNTX returned -54. 3% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CNTX or AGEN?
By beta (market sensitivity over 5 years), Context Therapeutics Inc.
(CNTX) is the lower-risk stock at 0. 46β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 492% more volatile than CNTX relative to the S&P 500.
04Which is growing faster — CNTX or AGEN?
On earnings-per-share growth, the picture is similar: Agenus Inc.
grew EPS 100. 0% year-over-year, compared to 17. 4% for Context Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CNTX or AGEN?
Agenus Inc.
(AGEN) is the more profitable company, earning 0. 1% net margin versus 0. 0% for Context Therapeutics Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNTX leads at 0. 0% versus -18. 0% for AGEN. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CNTX or AGEN more undervalued right now?
Analyst consensus price targets imply the most upside for CNTX: 125.
3% to $5. 25.
07Which pays a better dividend — CNTX or AGEN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CNTX or AGEN better for a retirement portfolio?
For long-horizon retirement investors, Context Therapeutics Inc.
(CNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46)). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNTX: -54. 3%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CNTX and AGEN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.